Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 1:9:950717.
doi: 10.3389/fmed.2022.950717. eCollection 2022.

Feasibility of sentinel lymph node mapping in ovarian tumors: A systematic review and meta-analysis of the literature

Saeideh Ataei Nakhaei  1 , Sayyed Mostafa Mostafavi  2 , Marjaneh Farazestanian  3 , Malihe Hassanzadeh  3 , Ramin Sadeghi  1
Affiliations

Feasibility of sentinel lymph node mapping in ovarian tumors: A systematic review and meta-analysis of the literature

Saeideh Ataei Nakhaei et al. Front Med (Lausanne). .

Abstract

Purpose of the report: Since the presence of lymph node metastases upstages the disease and to reduce the morbidity of total lymphadenectomy, sentinel lymph node (SLN) mapping in ovarian mass has been the focus of extensive research. This study aims to review all the literature associated with ovarian SLN mapping and assess the feasibility of ovarian SLN mapping.

Materials and methods: PubMed and Scopus were searched using the following keywords: (Sentinel lymph node) AND (Ovary OR Ovarian) AND (Tumor OR Neoplasm OR Cancer). All studies with information regarding sentinel node biopsy in ovaries were included. Different information including mapping material, injection sites, etc., was extracted from each study. In total, two indices were calculated for included studies: detection rate and false-negative rate. Meta-analysis was conducted using Meta-MUMS software. Pooled detection rate, sensitivity, heterogeneity, and publication bias were evaluated. Quality of the studies was evaluated using the Oxford center for evidence-based medicine checklist.

Results: Overall, the systematic review included 14 studies. Ovarian SLN detection rate can vary depending on the type of tracer, site of injection, etc., which signifies an overall pooled detection rate of 86% [95% CI: 75-93]. The forest plot of detection rate pooling is provided (Cochrane Q-value = 31.57, p = 0.003; I2 = 58.8%). Trim and fill method resulted in trimming of 7 studies, which decreased the pooled detection rate to 79.1% [95% CI: 67.1-87.5]. Overall, pooled sensitivity was 91% [59-100] (Cochrane Q-value = 3.93; p = 0.41; I2 = 0%). The proportion of lymph node positive patients was 0-25% in these studies with overall 14.28%.

Conclusion: Sentinel lymph node mapping in ovarian tumors is feasible and seems to have high sensitivity for detection of lymph node involvement in ovarian malignant tumors. Mapping material, injection site, and previous ovarian surgery were associated with successful mapping. Larger studies are needed to better evaluate the sensitivity of this procedure in ovarian malignancies.

Keywords: lymphatic mapping; lymphoscintigraphy; meta-analysis; nuclear medicine; ovarian cancer; sentinel node; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flow chart of the study selection.
FIGURE 2
FIGURE 2
Forest plot of detection rate pooling.
FIGURE 3
FIGURE 3
Funnel plot of detection rate pooling using trim and fill method.
FIGURE 4
FIGURE 4
Different sites of tracer injection.
FIGURE 5
FIGURE 5
Pooled sensitivity of the included studies for detection of involved nodes.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sadeghi R, Tabasi KT, Bazaz SM, Kakhki VR, Massoom AF, Gholami H, et al. Sentinel node mapping in the prostate cancer. Meta-analysis. Nuklearmedizin. (2011) 50:107–15. 10.3413/nukmed-0339-10-07 - DOI - PubMed
    1. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. (2000) 19:3–10. - PubMed
    1. Benedet J, Pecorelli S, Ngan H, Hacker NF, Denny L, Jones IIIHW, et al. Staging classifications and clinical practice guidelines for gynaecological cancers. Int J Gyneco Obstet. (2000) 70:207–312. - PubMed
    1. Kleppe M, Wang T, Van Gorp T, Slangen BF, Kruse AJ, Kruitwagen RF. Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecol Oncol. (2011) 123:610–4. - PubMed
    1. Takeshima N, Hirai Y, Umayahara K, Fujiwara K, Takizawa K, Hasumi K. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors. Gynecol Oncol. (2005) 99:427–31. - PubMed

Publication types